Figure 2

Human NSCs engraft widely and reduce infarct volume. I. (A) Infarct volume was reduced in hNSC-transplanted mice (MCAO/R + Tx) 24 hours post-transplantation (neurons are stained with cresyl violet, purple; infarct, white). (B) Quantification of II A. (n = 4, *P <0.05). (C) TTC staining (white, infarct). Shown are two representative samples of the same brain from anterior to posterior. A, anterior; P, posterior. II. (A) Diagram of brain and injection site. Arrowhead indicates NSC injection site; red dots, hNSC-disseminated areas. Ipsi, ipsilesional; Contra, contralesional. (B-H) hNSCs were identified with two different human-specific antibodies (human mitochondria, hMito or human cytoplasmic protein, Stem121). Three sampling sites are shown in rectangles, (C-H) higher magnification images: area 1, (no infarct), area 2 (infarct center), area 3 (peri-infarct). (B-E) Immunoreactivity to human mitochondria (hMito; DAB, brown) and (F-H) to Stem121 (G, H: green). Scale bars: B, 1 mm; E, 50 μm (10 μm inset); H, 100 μm (10 μm inset). DAB, 3,3-diaminobenzidine; MCAO/R, middle cerebral artery occlusion with reperfusion; NSCs, neural stem cells; TTC, triphenyl tetrazolium chloride; Tx: Transplantation.